Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Denise Partin

Nurse Practitioner, Family Medford, OR Nurse Practitioner

NPI 1962989913 CMS profile 10478438

825 Bennett Ave, Medford, OR 97504

Open in the dashboard

General payments

$7,382

102 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Denise Partin of Medford, OR is reported in the CMS Open Payments database as having received $7,382 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $188 8
2024 General $3,725 37
2023 General $405 21
2022 General $487 20
2021 General $2,577 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Denise Partin
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Denise Partin were reported at $188. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Denise Partin Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,577 $124 $35–$379 $132
2022 $487 $141 $44–$430 $149
2023 $405 $154 $49–$476 $160
2024 $3,725 $165 $51–$504 $164
2025 $188 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $3,050 20 payments
  2. Boston Scientific Corporation $2,649 12 payments
  3. Collegium Pharmaceutical, Inc. $434 36 payments
  4. Abbott Laboratories $317 4 payments
  5. Averitas Pharma Inc. $128 3 payments
  6. MML US, Inc. $114 1 payment
  7. Pfizer Inc. $110 3 payments
  8. Vertex Pharmaceuticals Incorporated $106 2 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $70 1 payment
  10. Nalu Medical, Inc. $68 3 payments
  11. Other $336 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $4,297 14 payments
  2. Food and Beverage $2,995 86 payments
  3. Education $90 2 payments
Products named General payments · program years 2021–2025
  1. SYNCHROMEDII $2,959 18 payments
  2. WAVEWRITER ALPHA Pain Management $1,326 4 payments
  3. WAVEWRITER ALPHA WaveWriter Alpha $969 3 payments
  4. BELBUCA $254 19 payments
  5. Qutenza $186 6 payments
  6. PROCLAIM $177 3 payments
  7. XTAMPZA $163 16 payments
  8. SPECTRA WAVEWRITER (REFURBISHED) $143 1 payment
  9. ETERNA $140 1 payment
  10. ReActiv8 $114 1 payment
  11. Other $864 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

7,123

Median for Nurse Practitioner: 389

Drug cost

$307,373

Median for Nurse Practitioner: $21,885

Branded share of claims

47.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 118 $55,456
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,135 $39,303
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,577 $38,818
Oxycodone Hcl Generic 1,292 $28,047
Nucynta Tapentadol Hcl Brand 28 $20,860
Buprenorphine Hcl Generic 307 $19,314
Xtampza Er Oxycodone Myristate Brand 26 $12,464
Morphine Sulfate Er Morphine Sulfate Brand 413 $10,674
Belbuca Buprenorphine Hcl Brand 11 $10,655
Fentanyl Generic 129 $10,644

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$84,203

Of which drugs: $21

Medicare patients

301

Average age 69

Services billed

1,621

203 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 38%
Diabetes 28%
COPD 28%
Osteoporosis 20%
Chronic kidney disease 18%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 13 25 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $95
$95 — —
NURTEC ODT
  • PFIZER INC. $82
$82 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $70
$70 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $58
$58 11 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $39
$39 26 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record